B.G. Verheggen

Cost effectiveness analysis of immunotherapy in patients with grass pollen allergic rhinoconjunctivitis in Germany

K.Y. Westerhout, B.G. Verheggen, C.H. Schreder et al. · Journal of Medical Economics · 2012 · 47 citations · Full text

Life Sciences, Immunology, Pharmacoeconomics +17

Health economic comparison of SLIT allergen and SCIT allergoid immunotherapy in patients with seasonal grass‐allergic rhinoconjunctivitis in Germany

B.G. Verheggen, K.Y. Westerhout, C.H. Schreder et al. · Clinical and Translational Allergy · 2015 · 38 citations · Full text

Life Sciences, Immunology, Pharmacoeconomics +17

Patient and physician preferences for oral pharmacotherapy for overactive bladder: two discrete choice experiments

M. Heisen, S. A. Baeten, B.G. Verheggen et al. · Current Medical Research and Opinion · 2016 · 18 citations

Medicine, Pharmacology, Pharmacotherapy +15

Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective

Ling‐Hsiang Chuang, B.G. Verheggen, M. Charokopou et al. · Journal of Medical Economics · 2016 · 18 citations

Pharmacy, Pharmacoeconomics, Pharmacotherapy +17

Cost-effectiveness of 3-year vs 1-year adjuvant therapy with imatinib in patients with high risk of gastrointestinal stromal tumour recurrence in the Netherlands; a modelling study alongside the SSGXVIII/AIO trial

István Májer, Hans Gelderblom, Wilbert B. van den Hout et al. · Journal of Medical Economics · 2013 · 17 citations

Pharmacy, Oncology, Pharmacoeconomics +17